Long-term experience with induction treatment regimens in multiple sclerosis.

Area of Science:

• Neuroimmunology
• Clinical Neurology
• Pharmacology

Background:

• The combination of induction and maintenance therapy is a key strategy for managing multiple sclerosis (MS).
• Mitoxantrone as induction therapy followed by immunomodulatory treatments like interferon-beta or glatiramer acetate is of significant clinical interest.
• This approach is particularly relevant for patients with aggressive MS phenotypes.

Observation:

• Aggressive MS is characterized by frequent relapses, incomplete recovery, and multiple gadolinium-enhancing T1 lesions on MRI.
• A short (six-month) course of mitoxantrone induction therapy leads to rapid disease activity reduction.
• Sustained disease control is observed for up to five years with subsequent immunomodulatory maintenance therapy.

Findings:

• Early treatment of aggressive MS with mitoxantrone induction and immunomodulatory maintenance yields the greatest clinical benefit.
• Randomized studies confirm that this combination therapy is superior to interferon-beta monotherapy for disease control.
• The recommended French protocol (six monthly mitoxantrone doses, 72 mg/m(2) cumulative) demonstrates good tolerability.

Implications:

• The findings support the use of mitoxantrone induction regimens for patients presenting with early signs of aggressive multiple sclerosis.
• This treatment strategy offers a viable option for achieving long-term disease control in high-risk MS patients.
• Early and aggressive treatment can significantly alter the disease course and improve patient outcomes.